Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M207200200 on October 31, 2002

J. Biol. Chem., Vol. 278, Issue 1, 263-269, January 3, 2003
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
278/1/263    most recent
M207200200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Teruel, T.
Right arrow Articles by Lorenzo, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Teruel, T.
Right arrow Articles by Lorenzo, M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Rosiglitazone and Retinoic Acid Induce Uncoupling Protein-1 (UCP-1) in a p38 Mitogen-activated Protein Kinase-dependent Manner in Fetal Primary Brown Adipocytes*

Teresa TeruelDagger§, Rosario HernandezDagger, Manuel Benito, and Margarita Lorenzo||

From the Departamento de Bioquimica y Biologia Molecular II, Facultad de Farmacia, Universidad Complutense, 28040 Madrid, Spain

Received for publication, July 18, 2002, and in revised form, October 29, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Brown adipose tissue expresses the thermogenic uncoupling protein-1 (UCP-1), which is positively regulated by peroxisome proliferator-activated receptor (PPAR) agonists and retinoids through the activation of the heterodimers PPAR/retinoid X receptor (RXR) and retinoic acid receptor (RAR)/RXR and binding to specific elements in the ucp-1 enhancer. In this study we show that in fetal rat brown adipocyte primary cultures the PPARgamma agonist rosiglitazone (Rosi), as well as retinoic acids 9-cis-retinoic acid and all-trans-retinoic acid also have "extragenic" effects and induce p44/p42 and p38 mitogen-activated protein kinase (p38MAPK) activation. The latter is involved in UCP-1 gene expression, because inhibition of p38MAPK activity with PD169316 impairs the ability of Rosi and retinoids for UCP-1 induction. The inhibitory effects of PD169316 are mimicked by the antioxidant GSH, suggesting a role for reactive oxygenated species (ROS) generation in the increase of UCP-1 expression in response either to Rosi or 9-cis-retinoic acid. Thus, we propose that Rosi and retinoids act as PPAR/RXR and RAR/RXR agonists and also activate p38MAPK. These two coordinated actions could result in a high increase of transcriptional activity on the ucp-1 enhancer and hence on thermogenesis. PPARalpha and gamma  agonists but not retinoids also increase UCP-3 expression in fetal brown adipocytes. However, the regulation of UCP-3, which is not involved in thermogenesis, seems to differ from UCP-1 given the fact that is not affected by p38MAPK inhibition.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Brown adipose tissue (BAT)1 is the main site for non-shivering thermogenesis in small mammals. This function relies on the presence of the tissue-specific uncoupling protein-1 (UCP-1), which is located in the mitochondrial inner membrane and stimulates heat production by uncoupling oxidative phosphorylation from the respiratory chain (1). UCP-1 expression is under complex regulation. An enhancer element in the 5'-flanking region of the ucp-1 gene has been described with putative binding sites for the thyroid hormone receptor (THR), retinoic acid (RA) receptors (RAR and RXR), and the peroxisome proliferator-activated receptor (PPAR) (2, 3). Although beta -adrenergic stimulation is the main physiological pathway that induces thermogenesis and UCP-1 expression in BAT, it is likely to be mediated by the induction of the PPARgamma coactivator (PGC-1), a master coactivator that binds PPARgamma , PPARalpha , THR, RAR, and RXR (4, 5). BAT also expresses the recently described UCP-2 and UCP-3, the latter being restricted to two thermogenic tissues (BAT and skeletal muscle). UCP-3 has shown to uncouple respiration when expressed ectopically in yeast and mammalian cells (6, 7), and a role for UCP-3 in the regulation of energy expenditure has been reported (8) as a response to nutritional states, with a key role for PPARalpha and PPARgamma ligands as positive regulators of UCP-3 gene expression (9, 10).

We have previously reported (11, 12) that the PPARgamma agonist, rosiglitazone (Rosi), increased UCP-1 and UCP-3 mRNA levels in fetal rat brown adipocytes prior to the acquisition of the catecholaminergic neuronal input. In contrast, the PPARalpha ligand Wy14643 induced UCP-3 but not UCP-1 expression, although it was able to transactivate the -4551UCP-1-chloramphenicol acetyltransferase (CAT) reporter gene (11, 12). The effect of Rosi on UCP-1 mRNA levels is mediated by increasing the transcription of the gene through the binding of the PPAR/RXR heterodimer to the PPAR response element (PPRE) described in the enhancer (2). PPREs have also been described in the 5'-flanking region of the human ucp-3 gene (13, 14). Among the coactivators that bind to PPAR, PGC-1 is highly expressed in BAT and plays a key role in adaptive thermogenesis. Because recent reports have described modulation either of PPARalpha , PPARgamma , and PGC-1 activity by phosphorylation via p44/p42 mitogen-activated protein kinase (MAPK) (15, 16), p38MAPK (17, 18), and/or protein kinase A (PKA) (19), we decided to explore the involvement of those kinases in the UCP-1 and UCP-3 induction by PPARgamma and alpha  agonists. This paper describes p38MAPK and p44/p42MAPK activation triggered either by Rosi or 9-cis-RA or all-trans-RA treatment in fetal rat brown adipocytes, with p38MAPK implication in UCP-1 but not UCP-3 expression.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- Wy14643 was from Biomol Research Laboratories (Plymouth, UK). Rosiglitazone was kindly provided by Dr. S. A. Smith (GlaxoSmithKline, Harlow, UK). PD169316 and PD98059 were purchased from Calbiochem-Novabiochem. Myelin basic protein (MBP), BSA, Bt2cAMP, 9-cis-RA and all-trans-RA were from Sigma. Fetal calf serum (FCS), phosphate buffered saline (PBS), culture media, and Trizol were from Invitrogen. Nylon membranes were GeneScreenTM (PerkinElmer Life Sciences). Autoradiographic films were Kodak X-O-MAT/AR (Eastman Kodak). [alpha -32P]dCTP, [gamma -32P]ATP, [14C]chloramphenicol, and the multiprimer DNA-labeling system kit were purchased from Amersham Biosciences. All other reagents used were of the purest grade available. The cDNAs used as probes were UCP-1, UCP-3, and fatty acid synthase (FAS) (12, 20, 21). The transfection MBS mammalian transfection kit was from Stratagene (La Jolla, CA). The plasmid constructs used for transfection experiments were -4551UCP-1-CAT, kindly provided by D. Ricquier (Meudon, France) (22) and pCMVbeta -galactosidase supplied by Stratagene. The anti-phospho- and anti-(p44/p42MAPK and p38MAPK) antibodies were from Cell Signaling (Beverly, MA). PPARgamma antibody "sc-1984" was from Santa Cruz Biotechnology.

Cell Culture-- Fetal brown adipocytes were obtained from interscapular brown adipose tissue of 20-day-old Wistar rat fetuses and isolated by collagenase dispersion as described (23). Isolated cells were plated at 1.5 × 106 cells/60-mm tissue culture dishes in 2.5 ml of minimal essential medium (MEM) with Earle's salts supplemented with 10% FCS, the presence of serum being essential for the attachment of cells to the plastic surface of the dishes. After 4-6 h of culture at 37 °C, cells were rinsed twice with PBS, and a 70% confluent monolayer was observed under inverse light microscopy. Cells were maintained for 20 h in a serum-free MEM supplemented with 0.2% (w/v) BSA before compound addition. Then, cells were further incubated for different times (from 1 to 24 h) in serum-free BSA-MEM supplemented or not with Rosi or Wy14643 or retinoids in either the presence or absence of several chemical inhibitors (PD169316 or PD98059 or H89).

RNA Extraction and Analysis-- For Northern-blot analysis of RNA, at the end of the culture time the cells were washed twice with ice-cold PBS and lysed directly with Trizol following the protocol supplied by the manufacturer for total RNA isolation (11). Total cellular RNA (15 µg) was submitted to Northern blot analysis, i.e. electrophoresed on 0.9% agarose gels containing 0.66 M formaldehyde, transferred to GeneScreenTM membranes using a VacuGene blotting apparatus (LKB-Pharmacia) and cross-linked to the membranes by UV light. Hybridization was in 0.25 mM NaHP04, pH 7.2, 0.25 M NaCl, 100 µg/ml denatured salmon sperm DNA, 7% SDS, and 50% deionized formamide containing denatured 32P-labeled cDNA (106 cpm/ml) for 24 h at 42 °C as described (24). Complementary DNA labeling was carried out with [alpha -32P]dCTP to a specific activity of 109 cpm/µg of DNA by using multiprimer DNA-labeling system kit. For serial hybridization with different probes, the blots were stripped and subsequently rehybridized as needed in each case. Membranes were subjected to autoradiography, and relative densities of the hybridization signals were determined by densitometric scanning of the autoradiograms in a laser densitometer (Amersham Biosciences).

Transfection Conditions-- The plasmid constructs used for transfection were -4551UCP-1-CAT, where the CAT reporter gene is under the control of a 4551 full-length 5'-flanking region of rat UCP-1, and pCMVbeta -galactosidase, a viral promoter-driven expression of the reporter gene beta -galactosidase. Fetal primary brown adipocytes were cultured for 24 h in the presence of 10%FCS-MEM and then transiently transfected according to the calcium phosphate-mediated protocol with 10 µg of DNA-CAT together with 2 µg of DNA-beta gal (to monitor transfection efficiency) as described previously (25). After 4 h of incubation, cells were shocked with 3 ml of 15% PBS-glycerol for 2 min, washed, and then fed with serum-free BSA-MEM medium (either in the absence or presence of Rosi ± PD169316) for 24 h. The cells were then harvested, and the lysates were prepared for CAT and beta -galactosidase activity assays. CAT activity was determined by incubating 50 µl of cell extracts with 0.25 µCi of [14C]chloramphenicol and 0.5 mM acetyl coenzyme A in 0.25 M Tris (pH 7.8) at 37 °C for 12 h, and samples were then submitted to thin layer chromatography. The amount of acetylated substrate was directly quantified with a radioimaging device (Fujifilm BAS-1000). CAT enzyme activity was expressed as a percentage of acetylated [14C]chloramphenicol normalized to the internal control, beta -galactosidase (assayed according to the Stratagene protocol). Routinely, we performed direct beta -galactosidase staining on parallel dishes, and observation under inverse light microscopy demonstrated that blue cells were mainly brown adipocytes with their characteristic multilocular fat droplets phenotype.

Western Blotting-- Cells were lysed in the lysis buffer (25 mM Hepes, 0.3 M NaCl, 20 mM glycerolphosphate, 0.2 mM EDTA, 0.1% Triton X-100, 0.5 mM dithiothreitol, 0.1 mM orthovanadate, 1 mM phenylmethylsulfonyl fluoride, 2 µg/ml leupeptin, pH 7.5), and the cellular proteins (30 µg) were submitted to SDS-PAGE, transferred to Immobilon membranes, and blocked using 5% nonfat dried milk in 10 mM Tris-HCl and 150 mM NaCl, pH 7.5, and incubated overnight with several antibodies as indicated in each case in 0.05% Tween 20, 1% nonfat dried milk in 10 mM Tris-HCl, and 150 mM NaCl, pH 7.5. Immunoreactive bands were visualized using the enhanced chemiluminiscence (ECL-Plus) Western blotting protocol (Amersham Biosciences).

p38MAPK Activity Assay-- Cells were extracted with lysis buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1% Triton X-100, 2 mM EDTA, 1 mM EGTA, 1 mM phenylmethylsulfonyl fluoride, 25 µg/ml leupeptin, and 25 µg/ml aprotinin) and immunoprecipitated with an anti-p38MAPK antibody as described (26). Immune complexes were washed five times with ice-cold lysis buffer with 0.5 M NaCl and two times with kinase buffer (35 mM Tris, pH 7.5, 10 mM MgCl2, 0.5 mM EGTA, 1 µM Na3VO4). The kinase reaction was performed in buffer containing 1 µCi of [gamma -32P]ATP, 60 µM ATP, and 1 µg of MBP as a substrate for 30 min at 30 °C, and it was terminated by the addition of 4× SDS-PAGE sample buffer followed by boiling for 5 min at 95 °C. Samples were resolved in 12% SDS-PAGE, and gels were dried out and subjected to autoradiography.

Gel Shift Assay-- Nuclear extracts were prepared as described previously (25). The UCP-1-PPRE double-stranded oligonucleotide, chemically synthesized by Sigma (Genosys), corresponds to positions -2485 to -2458 of the rat ucp-1 gene, and its sequence is 5'-GTGGGTCAGTCACCCTTGATCACACTGC-3'. The gel mobility shift assay was performed essentially as described previously (26). The gel was dried and subjected to autoradiography and also quantified directly with a radioimaging device.

Data Analysis-- Results are means ± S.E. (n = 6 or 8) for duplicate dishes from three or four independent experiments, respectively. Statistical significance was tested with a one-way analysis of variance followed by the protected least significant different test. p values less than 0.01 were considered significant. In experiments using x-ray films (Hyperfim), different exposure times were used to ensure that the bands were not saturated.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Fetal rat brown adipocytes, when isolated and allowed to attach to the plastic dishes for 4 h in 10% FCS-MEM, express adipogenic (FAS) and thermogenic (UCP-1) markers. After 20 h of culture in the absence of serum, UCP-1 mRNA levels decrease dramatically, facilitating the study of its up-regulation by several hormones/signals. Under these conditions, treatment for 24 h with noradrenaline or triiodothyronine or 9-cis-RA or insulin-like growth factor-1 is able to induce UCP-1 gene expression (27) (25). We have previously used the same culture conditions to demonstrate that Rosi per se and in the absence of any other exogenously added signal increases UCP-1 and UCP-3 mRNA levels in a time- and dose-dependent manner and induces activation of the full promoter UCP-1-CAT (11) (12). To explore the possible involvement of the extracellular signal regulated kinases (ERKs), p38MAPK, and/or PKA on UCP-1 induction by Rosi, we used chemical inhibitors for those kinases as follows: PD98059 (PD), 20 µM, to inhibit ERKs; PD169316 (PD*), 800 nM, as a p38MAPK inhibitor; and H89, 10 µM, to inhibit PKA activity. The efficiency of PD* and PD to inhibit p38MAPK activity and p44/p42MAPK phosphorylation at the doses used was tested in Fig. 3, B and C. Furthermore, H89 at 10 µM completely blocked UCP-1 mRNA induction as well as FAS mRNA repression by Bt2cAMP (Fig. 1B). Fetal rat brown adipocytes were treated for 24 h with or without 10 µM Rosi either in the absence or presence of the inhibitors. At the end of the culture period, total RNA was extracted and analyzed for UCP-1 expression by Northern blot (Fig. 1A). As expected, Rosi increased UCP-1 mRNA levels by 4-fold, and this effect was unmodified in the presence of PD or H89. However, the inhibition of p38MAPK activity with PD* resulted in a nearly complete blockade of UCP-1 induction by Rosi without a significant effect on the basal UCP-1 mRNA levels found in untreated cells. To validate whether the increase in UCP-1 expression produced by Rosi in a p38MAPK-dependent manner was independent of differentiation-inducing properties of Rosi or p38MAPK (28), the expression of the adipogenic marker FAS was also analyzed (Fig. 1A). Rosi treatment for 24 h did not induce FAS mRNA levels and did not increase intracellular lipid content (data not shown), indicating that the effects of Rosi are related to specific thermogenic gene expression rather than to a differentiation program. Furthermore, no changes on FAS mRNA expression were observed regardless of the presence or absence of the inhibitors (Fig. 1A).


View larger version (40K):
[in this window]
[in a new window]
  		Fig. 1.   Rosi induction of UCP-1 gene expression is dependent on p38MAPK activity but independent of p44/p42MAPK and PKA activities. Fetal brown adipocytes, after 20 h of serum deprivation in BSA-MEM medium, were cultured for 24 h in the absence or presence of 10 µM Rosi ± 20 µM PD or 800 nM PD* or 10 µM H89 (A) or for 6 h in the absence or presence of 0.5 mM Bt2cAMP ((Bu)2cAMP) ± 10 µM H89 (B). Total RNA was extracted from the different conditions, and 15 µg of it was submitted to Northern-blot analysis and hybridized with labeled UCP-1 and FAS cDNAs. A final hybridization with the 18 S rRNA cDNA was performed for normalization. Representative autoradiograms and densitometric analysis of UCP-1 mRNA levels after standardization using the 18 S rRNA signal are shown. Results (arbitrary densitometric units) are means ± S.E. (n = 8). Statistical significance was tested as described under "Experimental Procedures." The differences between values in the presence of Rosi versus control are represented by *, and the differences between values in the presence of Rosi plus inhibitors versus Rosi are represented by Delta . For * and Delta , p < 0.01.

We also performed transient transfections with -4551UCP-1-CAT (where the CAT reporter gene is under the control of a 4551-bp full-length 5'-flanking region of the rat UCP-1 promoter) to test whether the inhibition was produced on the transcription process. Fetal primary brown adipocytes were transiently co-transfected with 10 µg of -4551UCP-1-CAT together with 2 µg of pCMVbeta -galactosidase for internal control of transfection. Upon transfection, cells were cultured for 24 h in a serum-free BSA-MEM medium in the absence or presence of Rosi with or without PD169316. At the end of the culture period, cells were collected and assayed for CAT activity. As depicted in Fig. 2A, Rosi increased -4551UCP-1-CAT activity 3-fold, and this stimulation was totally precluded when the p38MAPK inhibitor was present in the culture medium. These results indicate that p38MAPK but not p44/p42MAPK or PKA activity is necessary for Rosi-induced UCP-1 gene transcription. To check whether the inhibition of p38MAPK was affecting the levels of the PPARgamma protein, a direct Western blot was performed (Fig. 2B). Similar PPARgamma protein content was detected in brown adipocytes either in the absence or presence of PD*. Furthermore, we checked whether nuclear protein binding to the PPRE of the UCP1 enhancer was affected by the inhibition of p38MAPK, either in the presence or absence of Rosi. Nuclear extracts from cells cultured for 24 h with or without Rosi and/or PD* were used in gel mobility shift assays using UCP-1-PPRE double-stranded oligonucleotide as a probe (Fig. 2C). Protein binding to DNA was observed in control brown adipocytes, and this binding was essentially unmodified either by the presence of Rosi or PD*. This band seems to be specific, because it disappears in competition experiments with a 100-fold molar excess of unlabeled PPRE probe.


View larger version (47K):
[in this window]
[in a new window]
  		Fig. 2.   PD169316 precludes Rosi-induced UCP-1 promoter activity. A, fetal brown adipocytes were transiently transfected with 10 µg of -4551UCP-1-CAT together with 2 µg of pCMVbeta -galactosidase for internal control of transfection. Upon transfection, cells were cultured for 24 h in a serum-free medium either in the absence (C) or presence of 10 µM Rosi ± 800 nM PD*. At the end of the cultured period, cells were collected and assayed for CAT activity as shown in a representative experiment. The relative CAT activity normalized to beta -galactosidase activity is represented in the histogram and results are means ± S.E. (n = 6). Statistical significance was tested as described under "Experimental Procedures," and the differences between values in the presence of Rosi versus control are represented by *, and the differences between values in the presence of Rosi plus PD* versus Rosi are represented by Delta . For * and Delta , p < 0.01. B, serum-starved fetal brown adipocytes were cultured for 24 h in the absence or presence of PD*. Total protein (30 µg) was submitted to SDS/PAGE, blotted onto nylon membrane, and immunodetected with the PPARgamma antibody. C, cells were treated for 24 h without (C) or with Rosi and/or PD*. Nuclear extracts (10 µg) were incubated for 20 min with 0.5 ng of 32P-labeled doubled-stranded oligonucleotide corresponding to UCP-1-PPRE. Nuclear extract from control cells was also incubated previously with unlabeled UCP-1-PPRE 100-fold molar excess for competition (Comp PPRE). The mixture was then electrophoresed through a 6% (w/v) polyacrylamide gel.

Many ligands for nuclear receptors act not only on gene expression activating nuclear receptors, but also affect cytosolic signaling pathways (29-31). To check the possibility that Rosi could be inducing p38MAPK activation, we treated brown adipocytes with Rosi for different period of time, and cell lysates were analyzed for dual phosphorylation (Thr-180/Tyr-182) of p38MAPK by Western blot with a polyclonal antibody. No phosphorylation of p38MAPK was detected in control cells cultured for 20 h in a serum-free BSA-MEM medium. However, Rosi treatment for 1 h induced p38MAPK phosphorylation, which was maintained up to 6 h (Fig. 3A). The changes observed in the amount of phospho-p38MAPK reflect changes in the activity, because the protein levels of p38MAPK are similar in all the conditions. Furthermore we performed p38MAPK activity assay with protein lysates from control cells and cells treated with Rosi for 3 h and obtained similar results. Rosi increased MBP phosphorylation 3-fold in anti-p38MAPK immunoprecipitates, and this activation was prohibited in cells cotreated with Rosi and PD*, validating the use of this chemical compound as a p38MAPK inhibitor (Fig. 3B). Western blot analysis with anti-phospho-p44/p42MAPK antibody revealed that the presence of Rosi for 3 h also increases p44/p42MAPK activity, which is further elevated after 6 h (Fig. 3C). This p44/p42MAPK activation is inhibited by PD, validating the use of this chemical compound in brown adipocytes. 0.1% Me2SO, the vehicle used, did not produce any effect (data not shown). These data clearly show that Rosi, besides being a PPARgamma agonist, stimulates kinase activities that can modulate its effects on gene expression.


View larger version (40K):
[in this window]
[in a new window]
  		Fig. 3.   Rosi induces p38MAPK and p44/p42MAPK activation in brown adipocytes. A and C, after 20 h of serum deprivation, fetal brown adipocytes were cultured in the absence or presence of 10 µM Rosi for 1, 3, and 6 h. A treatment for 6 h with Rosi+PD was also performed as shown in C. Total protein (30 µg) was submitted to SDS/PAGE, blotted onto nylon membrane, immunodetected with anti-phospho-p38MAPK, anti-p38MAPK, anti-phospho-p44/p42MAPK, or anti-p44/p42MAPK and developed with ECL chemiluminiscence. Representative autoradiograms (left panels) and densitometric analysis expressed as arbitrary units (means ± S.E. n = 6) (right panels) are shown. Statistical significance was tested as described under "Experimental Procedures," and differences between values in the presence of Rosi versus control are represented by *. For *, p < 0.01. B, serum-deprived cells were treated for 3 h in the absence (C) or presence of 10 µM Rosi ± 800 nM PD*, lysed, and immunoprecipitated with anti p38MAPK antibody. The resulting immune complexes were assayed for MBP phosphorylation. A representative experiment is shown (left panel) as well as the densitometric analysis (right panel) for p38MAPK activity. Results are phosphorylated MBP levels in arbitrary units and are the means ± S.E. (n = 8). Statistical significance was tested as described under "Experimental Procedures," and the differences between values in the presence of Rosi versus control are represented by *, and the differences between values in the presence of Rosi plus PD* versus Rosi are represented by Delta . For * and Delta , p < 0.01.

Although p38MAPK activation, but not p44/p42MAPK, is involved in UCP-1 gene induction by Rosi, this kinase does not play any role in UCP-3 expression either induced by Rosi or by the PPARalpha agonist Wy14643 as is assumed from the results obtained by Northern-blot analysis and represented in Fig. 4, where it is shown that UCP-3 expression is induced in cells treated with Rosi or Wy14643 regardless of the presence of the p38MAPK inhibitor PD169316.


View larger version (29K):
[in this window]
[in a new window]
  		Fig. 4.   Effects of the p38MAPK inhibitor PD169316 on UCP-1 and UCP-3 gene expression. After 20 h of serum deprivation, fetal brown adipocytes were cultured for 24 h with 10 µM Rosi or 10 µM Wy14643 (Wy) or 400 nM 9-cis-RA, or 400 nM all-trans-RA, both in the absence or presence of 800 nM PD*. Total RNA was extracted from the different conditions, and 15 µg was submitted to Northern blot analysis and hybridized with labeled UCP-1 and UCP-3 cDNAs. A final hybridization with the 18 S rRNA cDNA was performed for normalization. Representative autoradiograms are shown. Densitometric analysis of UCP-1 and UCP-3 mRNA levels after standardization using the 18 S rRNA signal are shown. Results (arbitrary densitometric units) are means ± S.E. (n = 8). Statistical significance was tested as described under "Experimental Procedures," and the differences between values in the presence of Rosi, Wy14643, 9-cis-RA, or all-trans-RA versus control are represented by *, and the differences between values in the presence of Rosi, Wy14643, 9-cis-RA, or all-trans-RA plus PD* versus the same treatment without PD* are represented by Delta . For * and Delta , p < 0.01.

Because PPARs bind to DNA as heterodimers taking RXR as partner, and RXR ligands also increase UCP-1 gene transcription, we wanted to check the possibility that p38MAPK activation was also involved in UCP-1 induction by RXR ligands. Brown adipocytes were cultured for 24 h with 9-cis-RA (agonist for RXR and RAR) or all-trans-RA (RAR agonist) in the absence or presence of the p38MAPK inhibitor (PD169316). Northern-blot analysis for UCP-1 expression revealed that 9-cis-RA treatment produced a huge increase in UCP-1 mRNA levels (12-fold) that was inhibited 50% in the presence of PD169316. The RAR agonist also induced UCP-1 expression but to a lesser extent than 9-cis-RA, this effect also being precluded by inhibition of p38MAPK. As previously published (12), none of the retinoids had any effect on UCP-3 expression (Fig. 4). Because p38MAPK activation also seemed to be involved in UCP-1 induction by retinoic acids, we decided to examine whether 9-cis-RA and all-trans-RA also activated p38MAPK; this was monitored by a Western blot of phosphorylated p38MAPK. As shown in Fig. 5, 9-cis-RA induced p38MAPK phosphorylation with a timing pattern similar to Rosi. p44/p42MAPK activation was also observed upon 9-cis-RA stimulation. Regarding all-trans-RA, it also activated p44/p42MAPK and p38MAPK but less strongly than 9-cis-RA.


View larger version (37K):
[in this window]
[in a new window]
  		Fig. 5.   9-cis-RA and all-trans-RA induce p38MAPK and p44/p42MAPK phosphorylation. Fetal brown adipocytes, after 20 h of serum deprivation, were cultured in the absence or presence of 400 nM 9-cis-RA or 400 nM all-trans-RA for 1, 3, and 6 h. Total protein (30 µg) was submitted to SDS/PAGE, blotted onto nylon membrane, immunodetected with anti-phospho-p38MAPK (P-p38MAPK) or anti-p38MAPK (A) or anti-phospho-p44/p42MAPK (P-p44MAPK, P-p42MAPK) or anti-p44/p42MAPK (B) and developed with ECL chemiluminiscence. Representative autoradiograms (left panels) and densitometric analysis expressed as arbitrary units (means ± S.E. n = 6) (right panels) are shown. Statistical significance was tested as described under "Experimental Procedures," and the differences between values in the presence of 9-cis-RA or all-trans-RA versus control are represented by *. For *, p < 0.01.

A very recent paper, which showed that MAPK activation by the PPARgamma agonists 15-deoxy-Delta 12,14-prostaglandin J2 (dPGJ2) and ciglitazone is produced through a mechanism involving reactive oxygenated species (ROS) (32), prompted us to examine whether ROS generation could be involved in UCP-1 induction by Rosi and/or retinoic acids. Brown adipocytes were or were not pretreated 30 min with an antioxidant agent, reduced GSH, before the addition of Rosi or 9-cis-RA and further cultured for 24 h. UCP-1 expression was analyzed by Northern-blot, and the results depicted in Fig. 6 show that the presence of GSH inhibited the increase in UCP-1 mRNA levels elicited by either Rosi or 9-cis-RA.


View larger version (55K):
[in this window]
[in a new window]
  		Fig. 6.   GSH impairs Rosi and 9-cis-RA induction of UCP-1. Fetal brown adipocytes, after 20 h of serum deprivation, were pretreated or not with 0.5 mM reduced GSH and further cultured for 24 h with 10 µM Rosi or 400 nM 9-cis-RA. Total RNA was extracted from the different conditions, and 15 µg of it was submitted to Northern blot analysis and hybridized with labeled UCP-1 cDNA. A final hybridization with the 18 S rRNA cDNA was performed for normalization. A representative autoradiogram and a densitometric analysis of the UCP-1 mRNA level after standardization using the 18 S rRNA signal are shown. Results (arbitrary densitometric units) are means ± S.E. (n = 6). Statistical significance was tested as described under "Experimental Procedures," and the differences between values in the presence of Rosi or 9-cis-RA versus control are represented by *, and the differences between values in the presence of Rosi or 9-cis-RA plus GSH versus the same treatment without GSH are represented by Delta . For * and Delta , p < 0.01.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Nuclear PPARs activate the transcription of multiple genes involved in lipid metabolism as well as the thermogenic protein UCP-1 and the recently described UCP-2 and UCP-3. PPARs are activated by ligand binding, which induces conformational changes leading to the recruitment of several coactivators (33). Furthermore, some agonists for PPARs, including the prostaglandin 15d-PGJ2 and the thiazolidinediones ciglitazone, pioglitazone, and troglitazone, have shown PPAR-independent effects, activating different cytosolic signaling pathways (ERK or c-Jun NH2-terminal kinase or p38MAPK) depending on the cellular system (30, 32, 34). It has also been reported that retinoic acids induce ERKs and p38MAPK activation in some cellular systems (29, 31, 35). To our knowledge, the results presented in this study describe for the first time p44/p42 and p38MAPK activation by 9-cis-RA and all-trans-RA as well as Rosi in fetal rat brown adipocytes. Kinetics for both activations are different. Meanwhile p38MAPK activation is rapid and sustained, whereas p44/p42MAPK phosphorylation delays and happens gradually. The biological effects of p44/p42MAPK activation are unknown. Phosphorylation by p44/p42MAPK can modulate PPAR activity, both in a positive and negative manner (15, 16). Nevertheless, from our results we conclude that this kinase is not involved in UCP-1 gene expression, but other effects remain unexplored. On the contrary, the timing of p38MAPK phosphorylation by Rosi fits tightly to the time frame for UCP-1 gene induction (11), and inhibition of p38MAPK activity prevents UCP-1 mRNA increase by this thiazolidinedione or retinoids. This effect seems to be specific for the thermogenic protein UCP-1 and not related to the differentiation-inducing properties of Rosi or p38MAPK, because the expression of the adipogenic gene FAS remains unmodified by either the presence of Rosi or PD* in fetal rat brown adipocytes.

p38MAPK activation via PKA in beta -adrenergic UCP-1 gene induction in post-natal mouse brown adipocytes has been reported (36). We have discarded the implication of PKA in UCP-1 induction by Rosi in fetal rat brown adipocytes, because H89 did not produce any effect. However, it is possible that different mechanisms operate in fetal as compared with post-natal brown adipocytes differentiated in culture. ROS generation has been involved in p38MAPK activation by ciglitazone and 15d-PGJ2 (32). Although we have not measured ROS formation by Rosi, the fact that the antioxidant GSH prevents UCP-1 induction by this thiazolidinedione in a similar fashion as that of the p38MAPK inhibitor suggests a role for ROS in the action of Rosi in fetal brown adipocytes. These are preliminary results that obviously deserve future study.

The inhibition of rosiglitazone-induced UCP-1 by PD* is not mediated by changes either in PPARgamma levels or in nuclear protein binding to UCP-1-PPRE. However, we cannot exclude the possibility that PD* could be blocking the binding of Rosi to PPARgamma , although it does not seem likely because other effects of Rosi (such as UCP-3 induction) are not modified by the presence of PD*. PPAR, RXR, and RAR bind PGC-1, a master coactivator involved in thermogenesis and UCP-1 expression. PGC-1 has been shown to be susceptible to phosphorylation by p38MAPK, resulting in a positive regulation of its transcriptional activity (18, 37). Therefore, it is tempting to speculate that Rosi and retinoids would act by two convergent mechanisms: 1) binding to specific nuclear receptors; and 2) switching on signaling pathways (p38MAPK) that positively modulate coactivators involved in activating transcription of specific genes such as UCP-1. In contrast to our results, Oberkofler et al. (38) have reported that the inhibition of p38MAPK signaling decreases the stimulatory effects of PPARalpha agonists treatment on UCP-1 transcription without reducing the response to thiazolidinediones or retinoic acids. This study was performed in the human brown adipocyte cell line PAZ6 co-transfected with expression vectors for h-PGC-1 and UCP-1-reported plasmids, whereas our experimental conditions are closer to a physiological situation because the primary culture is used with no exogenously expressed protein. These differences or even cell type (human versus rat) could explain the contrasting results. In any case, both studies show that p38MAPK activity regulates PPAR/RXR action on UCP-1 gene transcription.

Regarding UCP-3, we show that both Rosi and Wy14643 (PPARgamma and PPARalpha agonists respectively) induce UCP-3 expression, but the mechanism seems to differ from UCP-1 because p38MAPK inhibition does not affect the response. This could imply that there is no participation of PGC-1 in UCP-3 gene expression as has been reported in white adipose or skeletal muscle cells ectopically expressing PGC-1 (4, 39) or even that the PPRE found in the ucp-3 promoter is not functional and that other response elements are responsible for Rosi- or Wy14643-induced UCP-3 gene expression as was reported for UCP-2 (40). In conclusion, Rosi or retinoid treatment activates p44/p42MAPK and p38MAPK, the latter being involved in UCP-1 but not in UCP-3 gene expression in fetal rat brown adipocytes.

    ACKNOWLEDGEMENT

We thank the Cooperation in the Field of Scientific and Technical Research (COST) B17 Action (Insulin Resistance, Obesity and Diabetes Mellitus in the Elderly) from the European Commission.

    FOOTNOTES

* This work was supported by Direccion General de Investigacion Cientifica, Ministerio de Ciencia y Tecnologia (Spain) Grants PM1998-0082 and BMC2002-01322.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger These authors contributed equally to this experimental work.

§ Recipient of a postdoctoral fellowship from the Comunidad Autonoma de Madrid.

Recipient of a postgraduate fellowship from the Ministerio de Educacion y Cultura.

|| To whom correspondence should be addressed. Tel.: 34-913941858; Fax: 34-913941779; E-mail: mlorenzo@farm.ucm.es.

Published, JBC Papers in Press, October 31, 2002, DOI 10.1074/jbc.M207200200

    ABBREVIATIONS

The abbreviations used are: BAT, brown adipose tissue; BSA, bovine serum albumin; CAT, chloramphenical acetyltransferase; ERK, extracellular signal-regulated kinase; FAS, fatty acid synthase; FCS, fetal calf serum; MAPK, mitogen-activated protein kinase; MBP, myelin basic protein; MEM, minimal essential medium; PBS, phosphate-buffered saline; PD, PD98059; PD*, PD169316; PGC-1, PPARgamma coactivator; PKA, protein kinase A; PPAR, peroxisome proliferator-activated receptor; PPRE, PPAR response element; RA, retinoic acid; RAR, RA receptor; ROS, reactive oxygenated species; Rosi, rosiglitazone; RXR, retinoid X receptor; UCP, uncoupling protein.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Kozak, L. P., and Harper, M. E. (2000) Annu. Rev. Nutr. 20, 339-363[CrossRef][Medline] [Order article via Infotrieve]
2. Sears, I. B., MacGinnitie, M. A., Kovacs, L. G., and Graves, R. A. (1996) Mol. Cell. Biol. 16, 3410-3419[Abstract]
3. Silva, J. E., and Rabelo, R. (1997) Eur. J. Endocrinol. 136, 251-264[Abstract/Free Full Text]
4. Puigserver, P., Wu, Z., Park, C. W., Graves, R., Wright, M., and Spiegelman, B. M. (1998) Cell 92, 829-839[CrossRef][Medline] [Order article via Infotrieve]
5. Vega, R. B., Huss, J. M., and Kelly, D. P. (2000) Mol. Cell. Biol. 20, 1868-1876[Abstract/Free Full Text]
6. Boss, O., Samec, S., Kuhne, F., Bijlenga, P., Assimacopoulos-Jeannet, F., Seydoux, J., Giacobino, J. P., and Muzzin, P. (1998) J. Biol. Chem. 273, 5-8[Abstract/Free Full Text]
7. Gong, D. W., He, Y., Karas, M., and Reitman, M. (1997) J. Biol. Chem. 272, 24129-24132[Abstract/Free Full Text]
8. Clapham, J. C., Arch, J. R., Chapman, H., Haynes, A., Lister, C., Moore, G. B., Piercy, V., Carter, S. A., Lehner, I., Smith, S. A., Beeley, L. J., Godden, R. J., Herrity, N., Skehel, M., Changani, K. K., Hockings, P. D., Reid, D. G., Squires, S. M., Hatcher, J., Trail, B., Latcham, J., Rastan, S., Harper, A. J., Cadenas, S., Buckingham, J. A., Brand, M. D., and Abuin, A. (2000) Nature 406, 415-418[CrossRef][Medline] [Order article via Infotrieve]
9. Pedraza, N., Solanes, G., Carmona, M. C., Iglesias, R., Vinas, O., Mampel, T., Vazquez, M., Giralt, M., and Villarroya, F. (2000) Diabetes 49, 1224-1230[Abstract]
10. Brun, S., Carmona, M. C., Mampel, T., Vinas, O., Giralt, M., Iglesias, R., and Villarroya, F. (1999) Diabetes 48, 1217-1222[Abstract]
11. Teruel, T., Clapham, J. C., and Smith, S. A. (1999) Biochem. Biophys. Res. Commun. 264, 311-315[CrossRef][Medline] [Order article via Infotrieve]
12. Teruel, T., Smith, S. A., Peterson, J., and Clapham, J. C. (2000) Biochem. Biophys. Res. Commun. 273, 560-564[CrossRef][Medline] [Order article via Infotrieve]
13. Acin, A., Rodriguez, M., Rique, H., Canet, E., Boutin, J. A., and Galizzi, J. P. (1999) Biochem. Biophys. Res. Commun. 258, 278-283[CrossRef][Medline] [Order article via Infotrieve]
14. Tu, N., Chen, H., Winnikes, U., Reinert, I., Pirke, K. M., and Lentes, K. U. (2000) Life Sci. 67, 2267-2279[CrossRef][Medline] [Order article via Infotrieve]
15. Adams, M., Reginato, M. J., Shao, D., Lazar, M. A., and Chatterjee, V. K. (1997) J. Biol. Chem. 272, 5128-5132[Abstract/Free Full Text]
16. Shalev, A., Siegrist-Kaiser, C. A., Yen, P. M., Wahli, W., Burger, A. G., Chin, W. W., and Meier, C. A. (1996) Endocrinology 137, 4499-4502[Abstract]
17. Barger, P. M., Browning, A. C., Garner, A. N., and Kelly, D. P. (2001) J. Biol. Chem. 276, 44495-44501[Abstract/Free Full Text]
18. Puigserver, P., Rhee, J., Lin, J., Wu, Z., Yoon, J. C., Zhang, C. Y., Krauss, S., Mootha, V. K., Lowell, B. B., and Spiegelman, B. M. (2001) Mol. Cell 8, 971-982[CrossRef][Medline] [Order article via Infotrieve]
19. Lazennec, G., Canaple, L., Saugy, D., and Wahli, W. (2000) Mol. Endocrinol. 14, 1962-1975[Abstract/Free Full Text]
20. Bouillaud, F., Ricquier, D., Thibault, J., and Weissenbach, J. (1985) Proc. Natl. Acad. Sci. U. S. A. 82, 445-448[Abstract/Free Full Text]
21. Amy, C. M., Witkowski, A., Naggert, J., Williams, B., Randhawa, Z., and Smith, S. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 3114-3118[Abstract/Free Full Text]
22. Cassard-Doulcier, A. M., Gelly, C., Fox, N., Schrementi, J., Raimbault, S., Klaus, S., Forest, C., Bouillaud, F., and Ricquier, D. (1993) Mol. Endocrinol. 7, 497-506[Abstract/Free Full Text]
23. Lorenzo, M., Valverde, A. M., Teruel, T., and Benito, M. (1993) J. Cell Biol. 123, 1567-1575[Abstract/Free Full Text]
24. Teruel, T., Valverde, A. M., Alvarez, A., Benito, M., and Lorenzo, M. (1995) Biochem. J. 310, 771-776
25. Teruel, T., Valverde, A. M., Navarro, P., Benito, M., and Lorenzo, M. (1998) J. Cell. Physiol. 176, 99-109[CrossRef][Medline] [Order article via Infotrieve]
26. Conejo, R., de Alvaro, C., Benito, M., Cuadrado, A., and Lorenzo, M. (2002) Oncogene 21, 3739-3753[CrossRef][Medline] [Order article via Infotrieve]
27. Lorenzo, M., Valverde, A. M., Teruel, T., Alvarez, A., and Benito, M. (1996) Cell Growth & Differ. 7, 1251-1259[Abstract]
28. Engelman, J. A., Lisanti, M. P., and Scherer, P. E. (1998) J. Biol. Chem. 273, 32111-32120[Abstract/Free Full Text]
29. Bost, F., Caron, L., Marchetti, I., Dani, C., Le, Marchand-Brustel, Y., and Binetruy, B. (2002) Biochem. J. 361, 621-627[CrossRef][Medline] [Order article via Infotrieve]
30. Takeda, K., Ichiki, T., Tokunou, T., Iino, N., and Takeshita, A. (2001) J. Biol. Chem. 276, 48950-48955[Abstract/Free Full Text]
31. Hong, H. Y., Varvayanis, S., and Yen, A. (2001) Differentiation 68, 55-66[CrossRef][Medline] [Order article via Infotrieve]
32. Lennon, A. M., Ramauge, M., Dessouroux, A., and Pierre, M. (2002) J. Biol. Chem. 277, 29681-29685[Abstract/Free Full Text]
33. Olefsky, J. M. (2000) J. Clin. Invest. 106, 467-472[Medline] [Order article via Infotrieve]
34. Wilmer, W. A., Dixon, C., Lu, L., Hilbelink, T., and Rovin, B. H. (2001) Biochem. Biophys. Res. Commun. 281, 57-62[CrossRef][Medline] [Order article via Infotrieve]
35. Alsayed, Y., Uddin, S., Mahmud, N., Lekmine, F., Kalvakolanu, D. V., Minucci, S., Bokoch, G., and Platanias, L. C. (2001) J. Biol. Chem. 276, 4012-4019[Abstract/Free Full Text]
36. Cao, W., Medvedev, A. V., Daniel, K. W., and Collins, S. (2001) J. Biol. Chem. 276, 27077-27082[Abstract/Free Full Text]
37. Knutti, D., Kressler, D., and Kralli, A. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 9713-9718[Abstract/Free Full Text]
38. Oberkofler, H., Esterbauer, H., Linnemayr, V., Strosberg, A. D., Krempler, F., and Patsch, W. (2002) J. Biol. Chem. 277, 16750-16757[Abstract/Free Full Text]
39. Wu, Z., Puigserver, P., Andersson, U., Zhang, C., Adelmant, G., Mootha, V., Troy, A., Cinti, S., Lowell, B., Scarpulla, R. C., and Spiegelman, B. M. (1999) Cell 98, 115-124[CrossRef][Medline] [Order article via Infotrieve]
40. Medvedev, A. V., Snedden, S. K., Raimbault, S., Ricquier, D., and Collins, S. (2001) J. Biol. Chem. 276, 10817-10823[Abstract/Free Full Text]

Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J EndocrinolHome page
K A. H Iwen, O. Senyaman, A. Schwartz, M. Drenckhan, B. Meier, D. Hadaschik, and J. Klein
Melanocortin crosstalk with adipose functions: ACTH directly induces insulin resistance, promotes a pro-inflammatory adipokine profile and stimulates UCP-1 in adipocytes
J. Endocrinol., March 1, 2008; 196(3): 465 - 472.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. GenomicsHome page
C. Rink, S. Roy, S. Khanna, T. Rink, D. Bagchi, and C. K. Sen
Transcriptome of the subcutaneous adipose tissue in response to oral supplementation of type 2 Leprdb obese diabetic mice with niacin-bound chromium
Physiol Genomics, November 21, 2006; 27(3): 370 - 379.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
J. J. Schlezinger, J. K. Emberley, and D. H. Sherr
Activation of Multiple Mitogen-Activated Protein Kinases in Pro/Pre-B Cells by GW7845, a Peroxisome Proliferator-Activated Receptor {gamma} Agonist, and Their Contribution to GW7845-Induced Apoptosis
Toxicol. Sci., August 1, 2006; 92(2): 433 - 444.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
R. J Deckelbaum, T. S Worgall, and T. Seo
n-3 Fatty acids and gene expression
Am. J. Clinical Nutrition, June 1, 2006; 83(6): S1520 - 1525S.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
O. S. Gardner, B. J. Dewar, and L. M. Graves
Activation of Mitogen-Activated Protein Kinases by Peroxisome Proliferator-Activated Receptor Ligands: An Example of Nongenomic Signaling
Mol. Pharmacol., October 1, 2005; 68(4): 933 - 941.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
O. S. Gardner, C.-W. Shiau, C.-S. Chen, and L. M. Graves
Peroxisome Proliferator-activated Receptor {gamma}-independent Activation of p38 MAPK by Thiazolidinediones Involves Calcium/Calmodulin-dependent Protein Kinase II and Protein Kinase R: CORRELATION WITH ENDOPLASMIC RETICULUM STRESS
J. Biol. Chem., March 18, 2005; 280(11): 10109 - 10118.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
F. Felipe, M. L. Bonet, J. Ribot, and A. Palou
Modulation of Resistin Expression by Retinoic Acid and Vitamin A Status
Diabetes, April 1, 2004; 53(4): 882 - 889.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. M. Perez-Ortiz, P. Tranque, C. F. Vaquero, B. Domingo, F. Molina, S. Calvo, J. Jordan, V. Cena, and J. Llopis
Glitazones Differentially Regulate Primary Astrocyte and Glioma Cell Survival: INVOLVEMENT OF REACTIVE OXYGEN SPECIES AND PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-{gamma}
J. Biol. Chem., March 5, 2004; 279(10): 8976 - 8985.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
O. S. Gardner, B. J. Dewar, H. S. Earp, J. M. Samet, and L. M. Graves
Dependence of Peroxisome Proliferator-activated Receptor Ligand-induced Mitogen-activated Protein Kinase Signaling on Epidermal Growth Factor Receptor Transactivation
J. Biol. Chem., November 21, 2003; 278(47): 46261 - 46269.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
278/1/263    most recent
M207200200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Teruel, T.
Right arrow Articles by Lorenzo, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Teruel, T.
Right arrow Articles by Lorenzo, M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2003 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement